COMPANY & PRODUCT OVERVIEW

Traceable execution and quality

INTEGRETIX
CLINICAL TECHNOLOGY

Integretix develops practical digital tools for clinical trial oversight, quality workflows and trustworthy signing evidence

MISSION

Help promising therapies reach patients sooner by reducing preventable execution errors and gaps in supporting evidence.

THE OPPORTUNITY

Clinical operations and quality decisions depend on reliable, accessible evidence. Yet trial events, investigations and approvals often sit across disconnected workflows. Integretix is building complementary tools to strengthen visibility, accountability and documented review.

THREE COMPLEMENTARY PRODUCT DIRECTIONS

iCT

PROTOCOL-AWARE DIGITAL AUDITOR

Source-linked, preconfigured protocol checks are designed to flag potential timing, sequence and evidence gaps for qualified review.

PILOT DESIGN

iQMS

QUALITY MANAGEMENT SOLUTION

Structured Incident, Deviation, Change Control and CAPA workflows with audit trail and role-based approvals.

PILOT PREPARATION

DSS

DIGITAL SIGNATURE SOLUTION

Certificate-based document signing and associated signer/time metadata, designed to support controlled document processes.

CONTROL ENHANCEMENTS

iCT: FROM SOURCE EVENTS TO ACCOUNTABLE REVIEW

SOURCE EVENTS	PROTOCOL RULES	POTENTIAL FINDING	HUMAN REVIEW
Cross-system records and timestamps	Configured timing, sequence, completeness	Rule context and source-linked evidence	Qualified assessment and disposition

Automated alerts identify issues for review; they do not establish confirmed protocol deviations.

WHAT IS READY / NEXT

iCT has developed Corda backend and Android frontend proof-of-concept components; the URS, FS and configuration design are prepared. The next stage is selected-system integration and controlled pilot evaluation. AI-assisted resolution guidance is proposed for Phase 2.

HOW PARTNERS CAN EVALUATE VALUE

A scoped retrospective or parallel pilot can benchmark detection latency and accuracy, evidence traceability, investigation effort and time to disposition against existing oversight. Benefits are evaluation objectives, not established savings.

PILOT COLLABORATION & INVESTMENT INQUIRIES

Co-Founder & COO | Berlin, Germany | shalom.bashmet@integretix.com | integretix.com

Integretix GmbH